Sama

Sama Therapeutics is an AI/ML-enabled, precision neuropsychiatry platform. Neuropsychiatric disorders are the single largest cause of disability in the world, but current treatment paradigms rely heavily on the DSM-5-TR ("Diagnostic & Statistical Manual of Mental Disorders, 5th Edition, Text Revision), which often obscures heterogeneity within symptom clusters, along with high comorbidity across disorders. Standard of care proceeds via "trial & error", lacking objective neurobiological assessment to reliably guide clinical decision making. Sama Therapeutics synthesizes and validates predictive biomarkers grounded in neural (e.g. quantitative EEG), physiological (e.g. ECG), multi-omics, and behavioral data with the aim of increasing treatment efficacy and reducing costs by enhancing clinical trial stratification and target ID, optimal dosing, and endpoint identification to give trials the best chance at success. Sama's technology can accelerate pre/clinical development, discover fundamental neuroscience, and deliver patient clinical decision support. Software as medical device ("SaMD") -- Sama provides SaaS analytics on data that can be sent to them directly by clinicians, pharma, and device company clients and soon through t heir software platform after full commercialization. Sama also can collect and analyze biomarkers through their own clinical studies as they build toward accruing recurring revenue via licensing datasets, ML models, and biomarkers.